Cardiovascular risk and the COVID-19 pandemic: a population-based and case‒control studies.
COVID-19
Cardiovascular risk
Framingham Risk score
LIFE-CVD
SCORE2-OP
Journal
Population health metrics
ISSN: 1478-7954
Titre abrégé: Popul Health Metr
Pays: England
ID NLM: 101178411
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
23
10
2023
accepted:
14
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
19
7
2024
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic is associated with increases in morbidity and mortality worldwide. The mechanisms of how SARS-CoV-2 may cause cardiovascular (CV) complications are under investigation. The aim of the study was to assess the impact of the COVID-19 pandemic on CV risk. These are single-centre Bialystok PLUS (Poland) population-based and case‒control studies. The survey was conducted between 2018 and 2022 on a sample of residents (n = 1507) of a large city in central Europe and patients 6-9 months post-COVID-19 infection (n = 126). The Systematic Coronary Risk Estimation 2 (SCORE2), the Systematic Coronary Risk Estimation 2-Older Persons (SCORE2-OP), the Cardiovascular Disease Framingham Heart Study and the LIFEtime-perspective model for individualizing CardioVascular Disease prevention strategies in apparently healthy people (LIFE-CVD) were used. Subsequently, the study populations were divided into CV risk classes according to the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. The study population consisted of 4 groups: a general population examined before (I, n = 691) and during the COVID-19 pandemic (II, n = 816); a group of 126 patients post-COVID-19 infection (III); and a control group matched subjects chosen from the pre-COVID-19 pandemic (IV). Group II was characterized by lower blood pressure, low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) values than group I. Group III differed from the control group in terms of lower LDL-c level. There was no effect on CV risk in the general population, but in the population post-COVID-19 infection, CV risk was lower using FS-lipids, FS-BMI and LIFE-CVD 10-year risk scores compared to the prepandemic population. In all subgroups analysed, no statistically significant difference was found in the frequency of CV risk classes. The COVID-19 pandemic did not increase the CV risk calculated for primary prevention. Instead, it prompted people to pay attention to their health status, as evidenced by better control of some CV risk factors. As the COVID-19 pandemic has drawn people's attention to health, it is worth exploiting this opportunity to improve public health knowledge through the design of wide-ranging information campaigns.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic is associated with increases in morbidity and mortality worldwide. The mechanisms of how SARS-CoV-2 may cause cardiovascular (CV) complications are under investigation. The aim of the study was to assess the impact of the COVID-19 pandemic on CV risk.
METHODS
METHODS
These are single-centre Bialystok PLUS (Poland) population-based and case‒control studies. The survey was conducted between 2018 and 2022 on a sample of residents (n = 1507) of a large city in central Europe and patients 6-9 months post-COVID-19 infection (n = 126). The Systematic Coronary Risk Estimation 2 (SCORE2), the Systematic Coronary Risk Estimation 2-Older Persons (SCORE2-OP), the Cardiovascular Disease Framingham Heart Study and the LIFEtime-perspective model for individualizing CardioVascular Disease prevention strategies in apparently healthy people (LIFE-CVD) were used. Subsequently, the study populations were divided into CV risk classes according to the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
RESULTS
RESULTS
The study population consisted of 4 groups: a general population examined before (I, n = 691) and during the COVID-19 pandemic (II, n = 816); a group of 126 patients post-COVID-19 infection (III); and a control group matched subjects chosen from the pre-COVID-19 pandemic (IV). Group II was characterized by lower blood pressure, low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) values than group I. Group III differed from the control group in terms of lower LDL-c level. There was no effect on CV risk in the general population, but in the population post-COVID-19 infection, CV risk was lower using FS-lipids, FS-BMI and LIFE-CVD 10-year risk scores compared to the prepandemic population. In all subgroups analysed, no statistically significant difference was found in the frequency of CV risk classes.
CONCLUSIONS
CONCLUSIONS
The COVID-19 pandemic did not increase the CV risk calculated for primary prevention. Instead, it prompted people to pay attention to their health status, as evidenced by better control of some CV risk factors. As the COVID-19 pandemic has drawn people's attention to health, it is worth exploiting this opportunity to improve public health knowledge through the design of wide-ranging information campaigns.
Identifiants
pubmed: 39030517
doi: 10.1186/s12963-024-00338-w
pii: 10.1186/s12963-024-00338-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Subventions
Organisme : Medical University of Bialystok, Poland
ID : SUB/1/00/19/001/1201
Organisme : National Science Centre, Poland
ID : UMO-2020/37/B/NZ7/03380
Informations de copyright
© 2024. The Author(s).
Références
Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Jan M, Griffin JM, Amirali Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020;141:1648–55.
doi: 10.1161/CIRCULATIONAHA.120.046941
pubmed: 32200663
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80. e278.
doi: 10.1016/j.cell.2020.02.052
pubmed: 32142651
pmcid: 7102627
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.
doi: 10.1016/S2213-2600(20)30116-8
pubmed: 32171062
pmcid: 7118626
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–69.
doi: 10.1001/jama.2020.1585
pubmed: 32031570
pmcid: 7042881
Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond E, et al. Postcovid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.
doi: 10.1136/bmj.n693
pubmed: 33789877
Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583–90.
doi: 10.1038/s41591-022-01689-3
pubmed: 35132265
pmcid: 8938267
Chlabicz M, Jamiolkowski J, Laguna W, Dubatówka M, Sowa P, Łapińska M, et al. Effectiveness of Lifestyle Modification vs. therapeutic, preventative strategies for reducing Cardiovascular Risk in Primary Prevention-A Cohort Study. J Clin Med. 2022;11:688.
doi: 10.3390/jcm11030688
pubmed: 35160138
pmcid: 8836845
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.
doi: 10.1093/eurheartj/ehab484
pubmed: 34458905
Chlabicz M, Jamiolkowski J, Paniczko M, Sowa P, Szpakowicz M, Łapińska M, et al. ECG indices poorly predict left ventricular hypertrophy and are Applicable only in individuals with Low Cardiovascular Risk. J Clin Med. 2020;9:1364.
doi: 10.3390/jcm9051364
pubmed: 32384681
pmcid: 7290685
Chlabicz M, Jamiolkowski J, Laguna W, Sowa P, Paniczko M, Łapińska M, et al. A similar lifetime CV risk and a similar Cardiometabolic Profile in the Moderate and High Cardiovascular Risk populations: a Population-based study. J Clin Med. 2021;10:1584.
doi: 10.3390/jcm10081584
pubmed: 33918620
pmcid: 8069041
Chlabicz M, Jamiolkowski J, Paniczko M, Sowa P, Łapińska M, Szpakowicz M, et al. Independent Impact of Gynoid Fat Distribution and free testosterone on circulating levels of N-Terminal Pro-brain Natriuretic peptide (NT-proBNP) in humans. J Clin Med. 2019;9:74.
doi: 10.3390/jcm9010074
pubmed: 31892185
pmcid: 7020069
D’Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–53.
doi: 10.1161/CIRCULATIONAHA.107.699579
pubmed: 18212285
Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2020;41:1190–9.
doi: 10.1093/eurheartj/ehz239
pubmed: 31102402
Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, et al. The relationship of COVID-19 Severity with Cardiovascular Disease and its traditional risk factors: a systematic review and Meta-analysis. Glob Heart. 2020;15:64.
doi: 10.5334/gh.814
pubmed: 33150129
pmcid: 7546112
Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50:e13362.
doi: 10.1111/eci.13362
pubmed: 32726868
Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other preexisting comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS ONE. 2020;15:e0238215.
doi: 10.1371/journal.pone.0238215
pubmed: 32845926
pmcid: 7449476
Bilaszewski L, Timler W, Budrewicz K, Marczak M, Kozłowski R, Wizowska J, et al. The impact of COVID-19 on admissions and management of patients with Atrial Fibrillation Episodes in the Emergency Department. Int J Environ Res Public Health. 2021;18:6048.
doi: 10.3390/ijerph18116048
pubmed: 34199795
pmcid: 8200085
Romiti GF, Corica B, Lip GYH, Proietti M. Prevalence and impact of Atrial Fibrillation in Hospitalized patients with COVID-19: a systematic review and Meta-analysis. J Clin Med. 2021;10:2490.
doi: 10.3390/jcm10112490
pubmed: 34199857
pmcid: 8200114
Garcia-Zamora S, Lee S, Haseeb S, Bazoukis G, Tse G, Alvarez-Garcia J, et al. Arrhythmias and electrocardiographic findings in coronavirus disease 2019: a systematic review and meta-analysis. Pacing Clin Electrophysiol. 2021;44:1062–74.
doi: 10.1111/pace.14247
pubmed: 33890684
pmcid: 8250376
Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27:89–95.
doi: 10.1016/j.cmi.2020.09.023
pubmed: 32979574
Mozzini C, Cicco S, Setti A, Racanelli V, Vacca A, Calciano L, et al. Spotlight on Cardiovascular Scoring systems in Covid-19: severity correlations in real-world setting. Curr Probl Cardiol. 2021;46:100819.
doi: 10.1016/j.cpcardiol.2021.100819
pubmed: 33631706
pmcid: 7883723
Warren-Gash C, Davidson JA, Strongman H, Herrett E, Smeeth L, Breuer J, et al. Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. Lancet Reg Health Eur. 2023;27:100604.
doi: 10.1016/j.lanepe.2023.100604
pubmed: 36911072
pmcid: 9991014
Tao Z, Xu Q, Zhu Y, Mei Q, Feng H, Jin Q, et al. Relationship between health literacy and COVID-19 knowledge: a cross-sectional study. Front Public Health. 2023;11:1058029.
doi: 10.3389/fpubh.2023.1058029
pubmed: 36891332
pmcid: 9986311
Riegel B, Moser DK, Anker SD, Appel LJ, Dunbar SB, Grady KL, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120:1141–63.
doi: 10.1161/CIRCULATIONAHA.109.192628
pubmed: 19720935
Moser DK, Kimble LP, Alberts MJ, Alonzo A, Croft JB, Dracup K, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation. 2006;114:68–82.
doi: 10.1161/CIRCULATIONAHA.106.176040
Schiffl H, Lang SM. Long-term interplay between COVID-19 and chronic kidney disease. Int Urol Nephrol. 2023;55(8):1977–84.
doi: 10.1007/s11255-023-03528-x
pubmed: 36828919